Nurix Therapeutics Q2 net loss widens to $89.5 million; Roche deal pending
For the fiscal second quarter ended May 31, 2026, Nurix reported revenue of $9.0 million, down from $44.1 million a year earlier, and a net loss of $89.5 million ($0.81 per share), up from $43.5 million ($0.52 per share). The company also announced a global collaboration with Roche for bexobrutideg, with a $700 million upfront payment expected within 30 days after the agreement takes effect, subject to antitrust clearances.
Key points
- Revenue was $9.0 million versus $44.1 million; the prior-year period included $30 million of license revenue from two Sanofi license extensions.
- Net loss was $89.5 million, or $0.81 per share, compared with $43.5 million, or $0.52 per share, a year earlier.
- Roche collaboration covers bexobrutideg with potential total payments of up to $2.3 billion, including the $700 million upfront payment; closing requires Hart-Scott-Rodino clearance and other antitrust clearances.
- Cash, cash equivalents and marketable securities were $443.5 million at May 31, 2026, versus $592.9 million at November 30, 2025; the company expects the Roche upfront payment in its third fiscal quarter of 2026.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.